Expand early-stage human pluripotent stem cell (hPSC)-derived cardiomyocytes consistently using this serum-free kit. This kit generates a large number of functional and highly pure hPSC-derived cardiomyocytes and is compatible with ventricular or atrial cardiomyocytes generated with STEMdiff™ Ventricular Cardiomyocyte Differentiation Kit or STEMdiff™ Atrial Cardiomyocyte Differentiation Kit, respectively. Compared to the typical method of first expanding large numbers of hPSCs followed by multiple rounds of differentiation to yield high numbers of hPSC-derived cardiomyocytes, the STEMdiff™ Cardiomyocyte Expansion kit allows you to easily reach cardiomyocyte populations in the billions by simply expanding early-stage hPSC-derived cardiomyocytes with a single round of cardiomyocyte differentiation. Using this kit, expanded early-stage hPSC-derived cardiomyocytes retain a stable electrical profile and have cTnT percentages over 90% at passage 5. The expanded hPSC-derived cardiomyocytes are ready for high-throughput drug testing, tissue engineering, and regenerative medicine research.
By using this first-to-market kit to efficiently expand cardiomyocytes, you can save time and resources.
Create a complete, optimized workflow with these compatible STEMdiff™ cardiomyocyte products:
Area of Interest Disease Modeling, Drug Discovery and Toxicity Testing, Stem Cell Biology, Cell Therapy Development
Formulation Category Serum-Free
Data Figures
Figure 1. Workflow for the Expansion of Early-Stage hPSC-Derived Cardiomyocytes Using the STEMdiff™ Cardiomyocyte Expansion Kit
Expansion of early-stage human pluripotent stem cell (hPSC)-derived cardiomyocytes begins with the differentiation of hPSCs to cardiomyocytes using the STEMdiff™ Ventricular Cardiomyocyte Differentiation Kit or the STEMdiff™ Atrial Cardiomyocyte Differentiation Kit. On Day 11 of differentiation, a beating, confluent monolayer of early-stage cardiomyocytes can be observed. These cardiomyocytes are harvested and replated at low density to initiate expansion using STEMdiff™ Cardiomyocyte Expansion Kit. Expanding hPSC-derived cardiomyocytes can be passaged up to 5 times before switching to STEMdiff™ Cardiomyocyte Maintenance Medium for downstream assays.
Figure 2. Expanding hPSC-Derived Cardiomyocytes Are Confluent One Week After Replating with STEMdiff™ Cardiomyocyte Expansion Kit
Representative images of expanding hPSC-derived ventricular cardiomyocytes after replating at low density (Day 1) using STEMdiff™ Cardiomyocyte Passaging Medium. Cardiomyocyte confluency increases during the 7 day expansion period. On Day 7, a confluent monolayer of beating hPSC-derived cardiomyocytes is observed and the expanded hPSC-derived cardiomyocytes are ready for harvest.
Figure 3. Expansion of hPSC-Derived Cardiomyocytes Across Multiple Cell Lines with STEMdiff™ Cardiomyocyte Expansion Kit
(A) Expansion of hPSC-derived cardiomyocytes was tracked for 5 passages with 4 hPSC lines. Per passage, fold expansion is typically highest in the first 1 – 2 passages. (B) Cumulative fold expansion over 5 passages ranged from 33- to 103-fold expansion and averaged at 72-fold ± 12 (n = 15, 4 hPSC lines).
Figure 4. Cardiomyocyte Purity Increases During Expansion Using STEMdiff™ Cardiomyocyte Expansion Kit
Cardiomyocyte purity was tracked during expansion using STEMdiff™ Cardiomyocyte Expansion Kit for 5 passages on 4 hPSC lines. Throughout expansion, hPSC-derived cardiomyocytes express high levels of cardiac troponin T, and on average show an increase in cardiomyocyte purity during expansion. After 5 passages, cardiomyocyte cultures show an average cTnT purity of 90% ± 2% (n = 15).
Figure 5. Post-Expanded hPSC-Derived Cardiomyocytes Exhibit Typical Cardiac Electrophysiology and a Stable Beat Profile
Microelectrode Array (MEA) recordings of post-expanded hPSC-derived cardiomyocytes (using STEMdiff™ Cardiomyocyte Expansion Kit) exhibit a stable beat rate across 4 hPSC lines. The post-expanded hPSC-derived cardiomyocytes were replated onto MEA and maintained in STEMdiff™ Cardiomyocyte Maintenance Medium for 1 week. The average beat rate was 12 ± 1 beats per minute (n = 14, 4 hPSC lines).
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Thank you for your interest in IntestiCult™ Organoid Growth Medium (Human). Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they
can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our
privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
